Topics:
Breast Cancer • Medical Oncology
In a patient with metastatic HR+ breast cancer progressing on single agent AI, would you use a different AI with CDK4/6 inhibitor?
Is there any data to support this?
Answer from: Medical Oncologist at Academic Institution
I doubt that changing the AI would make a difference - in the EFECT trial, patients progressing or recurring on a nonsteroidal AI had a 3.7 month median TTP on exemestane (JCO 2007) (meaning that many patients had progressed by their first reassessment. The more intriguing question is...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
CDK4/6 inhibitors with their manageable toxicity and oral dosage constitute a very important treatment option for breast cancer patients and will continue to gain traction in the treatment of ER –positive breast cancer (currently being evaluated in early stage). However, I do not b...
Comments
Medical Oncologist at Missouri Cancer Associates
Thank you for the long discussion. I take it from ...
Thank you for the long discussion. I take it from ...
Medical Oncologist at Cleveland Clinic Florida
yes - I would . Thanks for your note The questi...
yes - I would . Thanks for your note The questi...